Clinical trial · Interventional
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
A Phase 1 Dose Escalation/Dose Finding Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
NCT05215574CI-TRIAL-00081477active not recruitingPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Conditions
Conditions (16)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bladder Urothelial Cancer | Bladder Urothelial Carcinoma | ALIAS | 0.90 |
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Cervical Cancer | Malignant Cervical Neoplasm | CURATED_EXACT | 0.92 |
| Cholangiocarcinoma | Cholangiocarcinoma | ONTOLOGY_EXACT | 0.98 |
| Colorectal Carcinoma | Colorectal Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Endocervical Cancer | Cervical Adenocarcinoma | ALIAS | 0.90 |
| Esophageal Cancer | Malignant Esophageal Neoplasm | CURATED_EXACT | 0.92 |
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
| Melanoma | Melanoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| NGM831 | Drug | — | UNRESOLVED |
| NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®) | Drug | — | UNRESOLVED |
| NGM831 plus pembrolizumab (KEYTRUDA®) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- NGM831 Monotherapy Dose Escalation
- description
- Part 1a Single Agent Dose Escalation
- interventionNames
- Drug: NGM831
- type
- EXPERIMENTAL
- label
- NGM831 combination dose finding with pembrolizumab (KEYTRUDA®)
- description
- Part 1b NGM831 plus pembrolizumab (KEYTRUDA®)
- interventionNames
- Drug: NGM831 plus pembrolizumab (KEYTRUDA®)
- type
- EXPERIMENTAL
- label
- NGM831 and NGM438 Combination Dose Finding with pembrolizumab (KEYTRUDA®)
- description
- Part 1c NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically or cytologically documented locally advanced or metastatic solid tumor malignancy. * Adequate bone marrow, kidney and liver function * Performance status of 0 or 1. * Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade 1 except for AEs not constituting a safety risk by Investigator judgement. Exclusion Criteria: * Prior treatment targeting ILT3. * Prior treatment targeting LAIR1.
References
Publications (0)
Data not yet available
No reference posted for this study.